| Literature DB >> 28886691 |
Laurence Tessier1, Olivier Côté1,2, Mary Ellen Clark1, Laurent Viel3, Andrés Diaz-Méndez3,4, Simon Anders5, Dorothee Bienzle6.
Abstract
BACKGROUND: Severe equine asthma is a naturally occurring lung inflammatory disease of mature animals characterized by neutrophilic inflammation, bronchoconstriction, mucus hypersecretion and airway remodeling. Exacerbations are triggered by inhalation of dust and microbial components. Affected animals eventually are unable of aerobic performance. In this study transcriptomic differences between asthmatic and non-asthmatic animals in the response of the bronchial epithelium to an inhaled challenge were determined.Entities:
Keywords: Asthma; Bronchus; Differential expression analysis; High-throughput nucleotide sequencing; Horse
Mesh:
Year: 2017 PMID: 28886691 PMCID: PMC5591550 DOI: 10.1186/s12864-017-4107-6
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Outline of study design and analysis
Fig. 3The individual change from pre- to post-challenge bronchoscopic score, pleural pressure, alveolar leukocyte concentration, proportion of neutrophils, and dynamic compliance differed significantly between asthmatic and control horses, while the change in lung resistance did not have a uniform pattern
Fig. 2Endoscopic appearance of bronchi (a), BAL lavage cell yield (b) and histological appearance of bronchial biopsies (c). Asthmatic horses had bronchoconstriction and increased secretions in airways after asthmatic challenge, while changes in horses without asthma consisted of mild bronchoconstriction (a). In asthmatic horses, cell concentration and proportion of neutrophils was increased in BAL fluid after challenge (b), and in bronchial biopsies epithelial basophilia and influx of submucosal leukocytes was evident (c)
Summary of RNA-seq reads mapped to the horse genome
| Sample | Total reads | Total mapped | Uniquely mapped | Multiple mapped |
|---|---|---|---|---|
| R1N1 | 30,751,400 | 29,497,889 (95.93%) | 28,289,828 (92%) | 1,208,061 (3.93%) |
| R2N1 | 29,096,094 | 27,924,026 (95.97%) | 26,796,723 (92.1%) | 1,127,303 (3.87%) |
| R1N2 | 32,809,322 | 31,473,113 (95.92%) | 30,216,857 (92.10%) | 1,256,256 (3.82%) |
| R2N2 | 36,872,731 | 35,096,310 (95.18%) | 33,642,523 (91.24%) | 1,453,787 (3.94%) |
| R1N3 | 33,871,258 | 32,377,015 (95.59%) | 31,022,612 (91.59%) | 1,354,403 (4.0%) |
| R2N3 | 33,703,288 | 32,248,448 (95.68%) | 30,927,028 (91.76%) | 1,321,420 (3.92%) |
| R1N4 | 28,780,180 | 27,551,694 (95.73%) | 26,196,530 (91.02%) | 1,355,164 (4.71%) |
| R2N4 | 37,016,186 | 35,272,681 (95.29%) | 33,603,034 (90.78%) | 1,669,647 (4.51%) |
| R1N5 | 44,838,345 | 42,510,917 (94.81%) | 40,489,583 (90.30%) | 2,021,334 (4.51%) |
| R2N5 | 48,307,368 | 45,988,565 (95.2%) | 43,877,495 (90.83%) | 2,111,070 (4.37%) |
| R1N6 | 47,157,281 | 44,765,270 (94.93%) | 42,647,415 (90.44%) | 2,117,855 (4.49%) |
| R2N6 | 51,788,389 | 49,290,097 (95.18%) | 47,078,696 (90.91%) | 2,211,401 (4.27%) |
| nR1N1 | 36,071,224 | 34,556,532 (95.8%) | 32,999,057 (91.48%) | 1,557,475 (4.32%) |
| nR2N1 | 37,488,512 | 35,847,340 (95.63%) | 34,102,178 (90.97%) | 1,745,162(4.66%) |
| nR1N2 | 34,952,730 | 33,371,917 (95.48%) | 31,645,390 (90.54%) | 1,726,527 (4.94%) |
| nR2N2 | 38,173,366 | 36,621,999 (95.93%) | 34,949,535 (91.55%) | 1,672,464 (4.38%) |
| nR1N3 | 37,452,422 | 36,033,693 (96.21%) | 34,446,130 (91.97%) | 1,587,563 (4.24%) |
| nR2N3 | 39,708,395 | 38,014,973 (95.73%) | 36,309,547 (91.44) | 1,705,426 (4.29%) |
| nR1N4 | 35,781,991 | 34,339,176 (96.37%) | 32,692,804 (91.37%) | 1,646,372 (5.0%) |
| nR2N4 | 34,901,655 | 33,484,332 (96.34%) | 31,867,656 (91.31%) | 1,616,676 (5.03%) |
| nR1N5 | 31,277,591 | 30,122,423 (96.3%) | 28,941,665 (92.53%) | 1,180,758 (3.77%) |
| nR2N5 | 35,994,809 | 34,677,174 (96.34%) | 33,341,679 (92.63%) | 1,335,495 (3.71%) |
| nR1N6 | 29,463,977 | 28,177,878 (95.64%) | 26,861,858 (91.17%) | 1,316,020 (4.47%) |
| nR2N6 | 35,834,021 | 34,358,029 (95.87%) | 32,871,846 (91.73%) | 1,486,183 (4.14%) |
| nR1N7 | 34,515,301 | 33,067,972 (95.81%) | 31,655,814 (91.72%) | 1,412,158 (4.09%) |
| nR2N7 | 25,962,392 | 24,914,311 (95.97%) | 23,840,642 (91.83%) | 1,073,669 (4.14%) |
Fig. 4EdgeR smear plot showing the log2 fold-change (FC, y-axis) versus the average log2 count per million (CPM, x-axis) of the change in gene expression due to challenge in all horses (a). Horizontal blue lines delineate 1-fold change and each point represents one gene. Differentially expressed genes are indicated in red (FDR <0.05). Genes with positive log2FC were up-regulated in asthmatic compared to non-asthmatic horses, while genes with negative FC were down-regulated. The majority of genes expressed differentially between the two groups are up-regulated. Leading logFC plot (b) shows individual horses with asthma before (black) and after (red) challenge, and horses without asthma before (blue) and after (green) challenge. No clustering was observed for non-asthmatic horses, but post- challenge samples from asthmatic horses are located distant from other samples
Fig. 5A heat map of differentially expressed genes significantly up- (a) and down-regulated (b) between asthmatic and non-asthmatic horses after challenge shows consistent change across individuals. Genes with positive log2FC were up-regulated in asthmatic compared to non-asthmatic horses, while genes with negative FC were down-regulated. Level of expression is expressed as cpm and ordered from highest (top) to lowest log2 fold-change (logFC, bottom). Significance threshold was set at FDR <0.05
Fig. 6Stacked bar chart of positive log2 fold-change (logFC) for genes differentially expressed between asthmatic and non-asthmatic horses in response to challenge. a ENSECAG00000014899; b ENSECAG00000017229
Fig. 7Stacked bar chart of negative log2 fold-change (logFC) for genes differentially expressed between asthmatic and non-asthmatic horses in response to challenge
Fig. 8Gene (a) and protein expression (b) of TNFRSF12A, PTCH1, CDC25A and IL8 in bronchial biopsies from horses with and without asthma. TNFRSF12A, CDC25A and IL8 mRNA, expressed as counts per million (CPM), was up-regulated in asthmatic and down-regulated in non-asthmatics following challenge, while PTCH1 was slightly down-regulated in asthmatics and up-regulated in non-asthmatics. (b) IHC results approximated gene expression with a relative increase in TNFRSF12A, CDC25A and IL8 immunoreactivity and decrease in PTCH1 immunoreactivity in asthmatic animals
Significantly over-represented biological processes identified by GO analysis
a Number of differentially expressed genes
b Classified as most specific (shaded)
The function of genes with overrepresented GO terms
| Gene symbol | Positive regulation of immune system process | Immune response | Inflammatory response | Positive regulation of response to external stimulus | Secretion | Positive regulation of apoptotic signalling pathway | Neutrophil chemotaxis | Positive regulation of blood coagulation | Association with asthma | Protein function (NCBI or Uniprot; |
|---|---|---|---|---|---|---|---|---|---|---|
| S100A9 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | Promotes inflammation with and without TLR4 interactions in a mouse model [ | Regulation of cellular processes such as cell cycle and differentiation. Antifungal and antibacterial activity |
| THBS1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | × | ✓ | Central in a network linked to pulmonary response to oxidative stress in asthma [ | Cell-to-cell and cell-to-matrix interactions |
| TLR4 | ✓ | ✓ | ✓ | ✓ | ✓ | × | × | ✓ | Linked to allergic asthma in a mouse model [ | Pathogen recognition and innate immunity |
| CXCL8 | ✓ | ✓ | ✓ | ✓ | × | × | ✓ | × | Biomarker of neutrophilic asthma in adult [ | Chemoattractant and angiogenic factor |
| C5AR1 | ✓ | ✓ | ✓ | ✓ | × | × | ✓ | × | Linked to regulation of airway remodelling [ | Receptor for C5a, ligand with chemotactic and inflammatory activity |
| MMP9 | ✓ | ✓ | ✓ | × | ✓ | ✓ | × | × | Increased in severe asthma, involved in Th2 response and EMT in human bronchial epithelial cells [ | Matrix metalloproteinase, breakdown of extracellular matrix |
| NLRP12 | ✓ | ✓ | ✓ | ✓ | ✓ | × | × | × | Increased expression in asthmatics on high-fat diet. No observed effect in allergic airway disease models [ | Anti-inflammatory molecule |
| TREM1 | ✓ | ✓ | × | × | ✓ | × | ✓ | × | Correlates with clinical stage and neutrophils in human asthmatics [ | Amplifies neutrophil and monocyte inflammatory response |
| PLEK | ✓ | × | × | × | ✓ | × | × | ✓ | NAa | EMT in bronchial epithelial cells [ |
| LGALS3 | ✓ | ✓ | × | × | × | × | ✓ | × | Key role in inflammation and airway remodelling in murine models of allergic asthma [ | Involved in apoptosis, innate immunity, cell adhesion and T-cell regulation |
| OSM | × | ✓ | × | ✓ | × | ✓ | × | × | Part of IL6 family of cytokines, OSM specifically is increased in asthmatics and correlates with irreversible airway obstruction [ | Inhibition of proliferation, regulation of production of other cytokines |
| PTGS2 | × | × | ✓ | ✓ | ✓ | × | × | × | Polymorphism in the gene associated with asthma and atopy in children [ | Prostaglandin biosynthesis |
| ORM1 | ✓ | × | ✓ | × | ✓ | × | × | × | NA | Acute-phase protein, potential immunosuppressive activity |
| IL1RN | × | ✓ | ✓ | × | ✓ | × | × | × | Sputum IL1RN to IL-1β ratio decreased in neutrophilic asthmatics compared to mixed neutrophilic and eosinophilic asthmatics [ | EMT in bronchial epithelial cells [ |
| CSF3R | ✓ | × | × | × | × | × | ✓ | × | NA | Controls granulocyte production and activity. |
| CXCR2 | × | × | ✓ | × | × | × | ✓ | × | Expression increased in sputum of patient with non-eosinophilic asthma [ | IL8 receptor, neutrophil migration |
| CAMP | × | ✓ | ✓ | × | × | × | × | × | NA | Response to pathogens, Antibacterial, regulation of cell chemotaxis and inflammation. |
| PTX3 | × | ✓ | ✓ | × | × | × | × | × | Expression increased in bronchial tissues of asthmatics and highly expressed in smooth muscle cells [ | Up-regulated in response to inflammation in epithelial cells. Role in angiogenesis and tissue remodelling. |
| MRGPRX2 | × | ✓ | × | × | ✓ | × | × | × | NA | IgE independent activation of mast-cells, leading to inflammation and smooth muscle cell contraction [ |
| AQP9 | × | ✓ | × | × | ✓ | × | × | × | NA | Neutrophil regulation [ |
| CLEC4E | ✓ | ✓ | × | × | × | × | × | × | NA | Inflammation |
| LILRB3 | ✓ | ✓ | × | × | × | × | × | × | NA | Inhibits immune response |
| CD300LB | ✓ | ✓ | × | × | × | × | × | × | NA | Expressed by granulocytes [ |
|
| ||||||||||
| TNFRSF12A | × | × | × | × | × | ✓ | × | × | NA | May be involved in angiogenesis, proliferation and cellular adhesion |
| SFN | × | × | × | × | × | ✓ | × | × | NA | Regulation of protein kinase C [ |
| PLAUR | × | × | × | × | × | ✓ | × | × | Increased expression in vitro in bronchial epithelium from asthmatics [ | Impaired wound repair process [ |
| OLR1 | × | × | ✓ | × | × | × | × | × | NA | Degradation of oxidized low-density lipoprotein |
| CCRL2 | × | × | ✓ | × | × | × | × | × | Expressed in lung epithelial cells and up-regulated following LPS exposure. Potential role in initiation of allergic inflammation [ | Unknown function, up-regulated in activated neutrophils |
| SERPINE2 | × | × | × | × | ✓ | × | × | × | Urokinase inhibitor [ | Serine protease inhibition |
| SRGN | × | × | × | × | ✓ | × | × | × | NA | Hematopoietic cell granule proteoglycan |
| TUBA4A | × | × | × | × | ✓ | × | × | × | NA | Component of microtubules |
| FCAR | × | ✓ | × | × | × | × | × | × | NA | Surface receptor of myeloid cells, regulation of immune defense processes |
| PADI4 | × | ✓ | × | × | × | × | × | × | NA | Required for NET formation [ |
| APOBEC3B | × | ✓ | × | × | × | × | × | × | NA | Up-regulated by PKC and increased likelihood of mutations [ |
| TREML4 | ✓ | × | × | × | × | × | × | × | NA | Immune response |
| CD300LD | ✓ | × | × | × | × | × | × | × | NA | Immune response |
| CD300A | ✓ | × | × | × | × | × | × | × | Co-aggregation of CD300A with CCR3 decreased clinical signs of asthma in a mouse model [ | Regulation of mast cell response [ |
| SLC46A2 | ✓ | × | × | × | × | × | × | × | NA | Potential transporter function |
| SAMSN1 | ✓ | × | × | × | × | × | × | × | NA | Cell proliferation, spreading and regulation of polarization |
| TREML2 | ✓ | × | × | × | × | × | × | × | Associated with asthma but not atopy in children [ | Surface receptor, role in innate and adaptive immune response |
a Not available
Fig. 9The main network cluster of genes DE between asthmatic and non-asthmatic horses after challenge. The network cluster is derived from 111 genes and contains 51 nodes each representing a protein, and 113 edges each representing an interaction between two proteins. Node color from white to green represents lowest to highest betweenness centrality (BC). The size of each node corresponds to the degree (number of connections). The color of edges represents the confidence of the interaction ranging from 0.4 (medium confidence, light gray) to 1 (highest confidence, black). Nodes with red borders have negative fold-change